Janus Henderson Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$162M Buy
209,248
+3,576
+2% +$2.74M 0.08% 222
2025
Q4
$159M Buy
205,672
+131,929
+179% +$89.6M 0.07% 219
2025
Q3
$41.5M Buy
73,743
+60,655
+463% +$34.3M 0.02% 451
2025
Q2
$6.87M Sell
13,088
-465
-3% -$260K ﹤0.01% 813
2025
Q1
$8.64M Buy
13,553
+80
+0.6% +$55K ﹤0.01% 740
2024
Q4
$9.6M Sell
13,473
-84,661
-86% -$71M ﹤0.01% 739
2024
Q3
$103M Sell
98,134
-2,290
-2% -$2.55M 0.05% 274
2024
Q2
$106M Sell
100,424
-3,568
-3% -$3.46M 0.06% 255
2024
Q1
$100M Sell
103,992
-8,837
-8% -$8.4M 0.05% 265
2023
Q4
$99.1M Sell
112,829
-9,584
-8% -$7.89M 0.06% 253
2023
Q3
$101M Buy
122,413
+35,120
+40% +$27.6M 0.07% 245
2023
Q2
$62.7M Sell
87,293
-109,778
-56% -$84.6M 0.04% 347
2023
Q1
$162M Sell
197,071
-49,951
-20% -$37.7M 0.11% 184
2022
Q4
$178M Sell
247,022
-323,524
-57% -$239M 0.13% 175
2022
Q3
$393M Buy
570,546
+415,027
+267% +$261M 0.15% 157
2022
Q2
$91.9M Sell
155,519
-13,183
-8% -$8.57M 0.06% 266
2022
Q1
$118M Sell
168,702
-10,276
-6% -$6.5M 0.06% 291
2021
Q4
$113M Sell
178,978
-18,668
-9% -$11.5M 0.05% 336
2021
Q3
$120M Sell
197,646
-10,300
-5% -$6.39M 0.05% 331
2021
Q2
$116M Sell
207,946
-26,381
-11% -$13.4M 0.05% 347
2021
Q1
$111M Sell
234,327
-147,496
-39% -$71.8M 0.05% 342
2020
Q4
$184M Buy
381,823
+40,236
+12% +$21.7M 0.09% 239
2020
Q3
$191M Buy
341,587
+46,572
+16% +$28.2M 0.1% 211
2020
Q2
$184M Buy
295,015
+257,084
+678% +$146M 0.1% 206
2020
Q1
$18.5M Buy
37,931
+9,363
+33% +$3.86M 0.01% 689
2019
Q4
$10.7M Sell
28,568
-203,166
-88% -$68.4M 0.01% 945
2019
Q3
$64.3M Sell
231,734
-66,398
-22% -$19.6M 0.03% 501
2019
Q2
$93.3M Sell
298,132
-132,020
-31% -$44M 0.05% 396
2019
Q1
$177M Sell
430,152
-505,998
-54% -$208M 0.1% 240
2018
Q4
$350M Sell
936,150
-605,891
-39% -$222M 0.22% 112
2018
Q3
$623M Sell
1,542,041
-260,699
-14% -$99.2M 0.33% 66
2018
Q2
$622M Buy
1,802,740
+203,306
+13% +$63.6M 0.35% 63
2018
Q1
$551M Sell
1,599,434
-74,406
-4% -$25.9M 0.32% 74
2017
Q4
$629M Buy
1,673,840
+128,510
+8% +$52M 0.38% 54
2017
Q3
$691M Sell
1,545,330
-17,640
-1% -$8.39M 0.44% 41
2017
Q2
$768M Buy
1,562,970
+1,552,948
+15,495% +$680M 0.52% 29
2017
Q1
$3.88M Buy
10,022
+200
+2% +$74.1K 0.03% 394
2016
Q4
$3.61M Buy
9,822
+402
+4% +$153K 0.03% 400
2016
Q3
$3.79M Hold
9,420
0.03% 375
2016
Q2
$3.29M Hold
9,420
0.03% 385
2016
Q1
$3.4M Sell
9,420
-18,879
-67% -$7.78M 0.03% 391
2015
Q4
$15.4M Buy
28,299
+4,129
+17% +$2.24M 0.12% 194
2015
Q3
$11.2M Buy
24,170
+14,358
+146% +$7.71M 0.1% 228
2015
Q2
$5.01M Sell
9,812
-1,394
-12% -$680K 0.04% 361
2015
Q1
$5.06M Hold
11,206
0.04% 362
2014
Q4
$4.6M Hold
11,206
0.03% 378
2014
Q3
$4.04M Hold
11,206
0.04% 310
2014
Q2
$3.17M Hold
11,206
0.03% 345
2014
Q1
$3.37M Buy
11,206
+2,150
+24% +$662K 0.03% 337
2013
Q4
$2.49M Hold
9,056
0.03% 363
2013
Q3
$2.83M Buy
9,056
+808
+10% +$213K 0.03% 336
2013
Q2
$1.9M Buy
+8,248
New +$1.92M 0.02% 387

Other funds holding REGN

Janus Henderson Group's REGN Position: Q1 2026 in Review

Janus Henderson Group increased its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q1 2026, buying an estimated $2.74M and bringing the position to 209,248 shares worth $162M. The position accounts for 0.08% of the portfolio, ranked #222.

Janus Henderson Group first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $768M in Q2 2017. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Janus Henderson Group held 209,248 shares of Regeneron Pharmaceuticals worth $162M as of Q1 2026.
  • Janus Henderson Group bought 3,576 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.74M.
  • Regeneron Pharmaceuticals made up 0.08% of Janus Henderson Group's portfolio in Q1 2026, its #222 holding.
  • Janus Henderson Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Janus Henderson Group's Regeneron Pharmaceuticals position peaked at $768M in Q2 2017.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.